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Abstract
Background: Malaria is on the increase due to emergence of  parasite drug resistance and there is thus an urgent need for 
the development of  new antiparasitic drugs effective at low concentrations. Ketolides antibiotics are used for treatment of  
various ailments and are relevant candidates to establish antiparasitic activity. 
Objectives: The present study investigates the activity of  ketolide compounds HMR 3004 and HMR 3647 (telithromycin) 
(0.025-12.5 µM) for activity against chloroquine-sensitive and resistant strains of  Plasmodium falciparum in vitro. 
Methods: The antiplasmodial activity of  the two ketolide agents were determined using microscopic and colorimetric [lac-
tate dehydrogenase assay] procedures. 
Results: Both HMR 3004 and HMR 3647 caused a dose-dependent inhibition of  growth of  both parasite strains with IC50 
values 3 and 15 nM, respectively. Suppression of  parasite growth was evident after 8 hours of  exposure to both agents at 
12.5 µM with total parasite clearance achieved at 40 hours. 
Conclusion: The results indicate lack of  cross-resistance between the ketolide compounds and chloroquine, implying pres-
ence of  a drug target different from that of  chloroquine. The particular drug target has still to be investigated but the 
stage-specific results indicate that it is expressed in all parasite growth phases. These observations demonstrate the anti-ma-
larial potential of  the ketolide antimicrobial agents.
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Introduction
According to the World Health Organization report, 
207 million new malaria cases were recorded in 20121. 
There has since been a observable decline in malaria 
cases that is attributable to proper intervention strat-
egies like introduction of  long-lasting insecticidal nets 
(LLINs) and artemisinin-based combination therapy 
(ACT)2,3,4,5. The relevance of  use of  ACT is currently 
challenged by recent reports of  reduced susceptibility 
and resistance in South-East Asia6,7. Drug development 
efforts are focused on the design of  compounds which 
have reduced toxicity and increased potency, as well as 
on the development of  agents which potentiate the ac-
tivities of  existing anti-malarial agents8. An alternative 
approach has been to examine the antiplasmodial po-
tential of  existing anti-bacterial agents9,10 and the rimi-
nophenazines that have shown promise11. Presently, the 
World Health Organization (WHO) prefers use of  arte-
misin in-based combination therapy (ACT) and hybrid 
molecules for tailored delayed acquisition of  resistance 
and/or curtailing it in totality12,13.   
Structural modification of  the prototype, 14-mem-
bered macrolide, erythromycin A, has led to the devel-
opment of  a novel class of  macrolide agents, the ke-
tolides. The major alteration characterising ketolides is 
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replacement of  the 3-cladinose of  the macrolide ring 
by a keto-group. Ketolides inhibit microbial growth 
by interfering with the translation of  messenger RNA, 
and exhibit increased potency, broadened antimicrobial 
spectrum and impressive accumulation in tissues and 
blood14,15,16,17.
Although the improved anti-bacterial properties of  
the ketolides are well-recognised and characterised, lit-
tle or no work appears to have been conducted on the 
anti-malarial potential of  these agents. In the current 
study, we have investigated the effects of  HMR 3004 
and HMR 3647 (Figure 1), which have a carbamate 
group at C11/C12 of  the lactone ring with alkyl-aryl 




Figure 1: Structures of erythromycin A, telithromycin (HMR 3647) and HMR 3004. 
Materials and methods
Parasites strains and culturing conditions.
 The chloroquine-resistant (FCR-3) and sensitive (FAB-
9) strains of  P. falciparum were maintained in a con-
tinuous culture system of  human erythrocytes (blood 
group O+ obtained from the SA Blood Transfusion 
Services) in RPMI 1640 culture medium supplemented 
with 2mM L-glutamine, 25 mM HEPES, 25 mM NaH-
CO3 and 10% human AB+ serum. The suspension 
was maintained at 37oC in an atmosphere of  5% O2/ 
5% CO2 / 90% N2
10. Cultures were monitored daily by 
microscopic analysis of  Giemsa-stained blood smears. 
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Parasites cultures were synchronised to the ring stage by 
treatment with 5% D-sorbitol10.
Antimicrobial agents.
HMR 3004 and HMR 3647 were provided by Prof. RA 
Anderson (Department of  Immunology, University of  
Pretoria, South Africa) and dissolved in 0.1 N HCl to 
give a stock solution of  5 g/l and further diluted in par-
asite culture medium. 
In vitro assays.
For these assays, 20 µl of  infected erythrocyte suspen-
sion (2% parasitemia and 0.5% final haematocrit) were 
exposed to 20 µl of  the ketolide compounds (0.025-
12.5 µM). Parasites (20µl) in culture medium (80µl) and 
culture medium alone (200µl) served as positive and 
negative controls respectively. Solvent controls were 
also run. After 48h incubation at 37OC, parasite growth 
was determined by microscopic evaluation of  Giem-
sa-stained slides and by use of  the LDH assay18. For 
the LDH assay, 20 µl of  the parasite culture suspension 
was added to 100 µl of  the Malstat reagent and colour 
change measured at 620 nm in a microplate spectropho-
tometer. The FCR-3 (chloroquine-resistant) laboratory 
strain of  P. falciparum was used for the stage-specif-
ic assays. Synchronised ring-stage parasite culture sus-
pensions (2% parasitemia and 0.5%  final haematocrit) 
were incubated with antimicrobial agents (12.5 µM) and 
parasite development monitored at 8 h intervals for 48 
hours using microscopy and colorimetry.  
Statistical analysis
Results are expressed as the mean value ±SEM for four 
experiments conducted in triplicate. The antiplasmodial 
activity of  the compounds was expressed as percentage 
parasite growth and the IC50 values calculated using a 
Graph Pad Prism software version 5.00. Levels of  sta-
tistical significance were calculated using Students t test 
(paired statistics), p≤0.05 was considered significant. 
 
Results
The effects of  the test agents on the growth of  the chlo-
roquine-sensitive and resistant strains of  P. falciparum 
as assessed by the colorimetric procedure are shown as 
IC50 values in Table 1. HMR 3004 and HMR 3647 ex-
hibited a dose-related antiplasmodial activity (p≤0.05) 
comparable to that of  chloroquine. HMR 3004 and 
HMR 3647 were also evaluated at 12.5 µM for in vitro 
stage-specific activity and the results are shown in Fig-
ure 2. After an 8 h incubation period, parasite growth 
was suppressed by more than 50% with extended treat-
ment leading to complete inhibition of  parasite growth 
at around 35 hours with both antimicrobial agents, in-
dicating a time dependent effect. These observations 
were confirmed by microscopy (data not shown).
 
Table 1: Effects of the compounds (0.025-12.5µM) HMR 3004 and HMR 3647 on the 
growth of the FAB-9 (chloroquine-sensitive) and FCR-3 (chloroquine-resistant) 
laboratory strains of P. falciparum. Data are expressed as mean IC50 values ± SEMs of 
four repeat experiments conducted in triplicates. Results on the activity of chloroquine not 
shown. 
 
                                                IC50 (nM) ± SEM____           _              
Strain________                           CQ_____HMR 3004                 HMR 3647 
FAB-9           31            3 ± 0.9             7 ± 0.12 
FCR-3           125          9 ± 2.1             15 ± 1.34 
  
  
African Health Sciences Vol 15 Issue 4, December 20151273
Discussion
The results of  the present study indicates that the ke-
tolide compounds HMR 3004 and HMR 3647 inhibit 
the growth of  P. falciparum in vitro at concentrations 
probably comparable to those of  chloroquine. Impor-
tantly, chloroquine-sensitive and resistant strains of  the 
parasite were equally affected by the ketolides, demon-
strating that the mechanisms of  antiplasmodial action 
of  these agents is likely to be distinct from that of  chlo-
roquine.
Antibiotics have been screened previously for in vitro 
antiplasmodial activity19,20,21,22. Of  interest in one of  the 
publications is the laboratory evaluation of  macrolide 
erythromycin and azithromycin for activity against ma-
laria parasites in combination with classical antimalar-
ials. This study did show synergistic and additive ac-
tivities of  drug interactions20. Our study unfortunately 
did not explore drug combination activities in vitro. 
Telithromycin was also assayed in both laboratory and 
 
  
Figure 2: Stage-specific antimalarial activity of ketolide compounds HMR 3004 and 
HMR 3647 (12.5& PubMed micro;M) on the FCR-3 laboratory strain of P. falciparum. 
Data from four repeat experiments with triplicate determinations in each are expressed as the 
mean percentage parasitemia of the control system ± SEMs. R2= coefficient of determination. 
a mice models of  malaria infection and did show ac-
tivities that are not comparable to that in our present 
study23,24. The differences in the results might be due to 
employment of  different experimental platforms and 
parasite strains. For example, the kinetics model ex-
tends to over 48 hours thus including the re-infection 
stage, which is dissimilar to the same assay in the pres-
ent study. The efforts to develop macrolides as antima-
larials have proved fruitless.  
HMR 3004 and HMR 3647 also inhibited the growth of  
the parasite increasingly with time, it does suggest that 
these chemicals inhibited parasite growth in a time-de-
pendent manner. The observation may indicate that the 
molecular targets of  these agents are expressed by the 
parasite and are affected as the parasite is exposed over 
time.
Ketolides inhibit bacterial growth by interfering with 
its ribosomal translation processes14. Plasmodium spp. 
have also been shown to express two forms of  riboso-
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mal RNA, A- and S-type RNA found in the asexual and 
sexual forms of  the parasite respectively17. Although 
these are potential targets of  the ketolides in the para-
site, existence of  alternative or additional targets cannot 
be excluded.
Conclusion
The ketolide antimicrobials HMR 3004 and HMR 3647 
possess antiparasite activity in vitro, and should further 
be evaluated with respect to molecular/biochemical 
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